



(12) **United States Patent**
Essack et al.

(10) **Patent No.:** **US 10,085,967 B2**
(45) **Date of Patent:** **Oct. 2, 2018**

(54) **TREATMENT OF SICKLE CELL DISEASE**

FOREIGN PATENT DOCUMENTS

(71) Applicant: **KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY**, Thuwal (SA)

WO WO-2004106325 A1 12/2004

(72) Inventors: **Megbubah Essack**, Thuwal (SA); **Vladimir Bajic**, Thuwal (SA); **Aleksandar Radovanovic**, Thuwal (SA)

OTHER PUBLICATIONS

(73) Assignee: **King Abdullah University of Science and Technology**, Thuwal (SA)

Charache et al., "Treatment of sickle cell anemia with 5-azacytidine results in increase fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the γ - α - β -globin gene complex", The Proceeding of the National Academy of Sciences of the USA, vol. 80, No. 15, pp. 4842-4846 (1983).*

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

Chokchaisiri et al., "Labdane Diterpenes for the Aerial Parts of Curcuma comosa Enhance Fetal Hemoglobin Production in an Erythroid Cell Line", Journal of Natural Products, vol. 73, No. 4, pp. 724-728 (2010).*

(21) Appl. No.: **15/483,306**

Fibach et al., "Enhanced Fetal Hemoglobin Production by Phenylacetate and 4-Phenylbutyrate in Erythroid Precursors Derived From Normal Donors and Patients With Sickle Cell and β -Thalassemia", Blood, vol. 82, No. 7, pp. 2203-2209 (1993).*

(22) Filed: **Apr. 10, 2017**

Chokchaisiri et al., "Labdane diterpenes from the aerial parts of Curcuma comosa enhance fetal hemoglobin production in an erythroid cell line", Journal of Natural Products, Apr. 23, 2010, vol. 73, No. 4, pp. 724-728.

(65) **Prior Publication Data**

US 2017/0209412 A1 Jul. 27, 2017

Cokic et al., "Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase", J Clin Invest, 2003, vol. 111, pp. 231-239.

Related U.S. Application Data

Olnes et al., "Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea" *Am J Hematol*, Aug. 2009, vol. 84, No. 8, pp. 530-532.

(62) Division of application No. 14/345,206, filed as application No. PCT/IB2012/002887 on Sep. 13, 2012, now Pat. No. 9,655,905.

Brawley et al., "National Institutes of Health Consensus Development Conference Statement: Hydroxyurea Treatment for Sickle Cell Disease", *Ann Intern Med*, Jun. 17, 2008, vol. 148, No. 12., pp. 932-938.

(60) Provisional application No. 61/534,449, filed on Sep. 14, 2011.

Haynes et al., "Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium", *American Journal of Physiology—Heart and Circulatory Physiology*, Jan. 1, 2008, vol. 294, No. H379-H385.

(51) **Int. Cl.**
A61K 31/34 (2006.01)
A61K 31/365 (2006.01)
A61K 45/06 (2006.01)
A61K 31/551 (2006.01)

Abraham et al., "Asymmetric synthesis of N,O,O-tetra-acetyl d-lyxo-phytosphingosine, jaspine B (pachastrissamine), 2-epi-jaspine B, and deoxoprosophylline via lithium amide conjugate addition", *Org. Biomol. Chem.*, 6:1665-1673, 2008.

(52) **U.S. Cl.**
CPC **A61K 31/365** (2013.01); **A61K 31/551** (2013.01); **A61K 45/06** (2013.01); **A61K 31/34** (2013.01)

Arita et al., "Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage", *Diabetes*, 58:215-226, 2009.

(58) **Field of Classification Search**
CPC A61K 31/34
USPC 514/461
See application file for complete search history.

Barabino et al., "Sickle cell biomechanics", *Annu. Rev. Biomed. Eng.*, 12:345-367, 2010.

(Continued)

(56) **References Cited**

Belcher et al., "Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice", *J. Clin. Invest.*, 116:808-816, 2006.

U.S. PATENT DOCUMENTS

Bernaudin et al., "Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease", *Blood* 110:2719-2756, 2007.

5,399,363	A	3/1995	Liversidge et al.
5,466,468	A	11/1995	Schneider et al.
5,543,158	A	8/1996	Gref et al.
5,580,579	A	12/1996	Ruddy et al.
5,641,515	A	6/1997	Ramtoola
5,725,871	A	3/1998	Illum
5,756,353	A	5/1998	Debs
5,780,045	A	7/1998	McQuinn et al.
5,792,451	A	8/1998	Sarubbi et al.
5,804,212	A	9/1998	Illum
6,613,308	B2	9/2003	Bartus et al.
6,737,514	B1	5/2004	Wang et al.
2007/0185045	A1	8/2007	Ratcliffe

Primary Examiner — Kevin E Weddington
(74) *Attorney, Agent, or Firm* — Pabst Patent Group LLP

(57) **ABSTRACT**

The present invention includes embodiments for treatment and/or prevention of sickle cell disease that employ Hydroxyfasudil or Isocoronarin D alone or either in conjunction with each other or an inducer of HbF production. The compounds may act synergistically, and the compounds employed circumvent the side effects seen with Hydroxyurea.

3 Claims, No Drawings